Skip to main content
. Author manuscript; available in PMC: 2016 Jul 19.
Published in final edited form as: Arthritis Rheumatol. 2015 Sep;67(9):2457–2465. doi: 10.1002/art.39220

Table 1.

Characteristics of the study participants*

CTD-associated PAH
Idiopathic PAH (n = 1,654) P, all CTD-associated PAH vs. idiopathic PAH
All (n = 716) SSc-associated PAH (n = 407) Non–SSc-associated PAH (n = 309)
Age, years 53 ± 14 59 ± 11 45 ± 14 46 ± 15 <0.001
Female sex, % 89 88 90 73 <0.001
Race, % 0.39
 White 71 88 49 73
 Black 5 4 6 4
 Other 25 8 45 23
Body mass index, kg/m2 26 ± 6 27 ± 6 26 ± 6 28 ± 7 <0.001
WHO functional class, % 0.18
 I–II 47 37 59 44
 III–IV 53 63 41 56
Baseline hemodynamics
 Right atrial pressure, mm Hg 8.0 ± 5.0 8.3 ± 4.9 7.7 ± 5.0 9.6 ± 5.8 <0.001
 Mean pulmonary arterial pressure, mm Hg 46 ± 12 45 ± 13 48 ± 12 56 ± 16 <0.001
 Cardiac index, liters/minute/m2 2.5 ± 0.8 2.5 ± 0.8 2.5 ± 0.8 2.3 ± 0.8 <0.001
 Pulmonary capillary wedge pressure, mm Hg 9 ± 4 10 ± 3 9 ± 3 9 ± 4 0.70
 Pulmonary vascular resistance, Wood units 10.2 ± 6.2 9.6 ± 6.4 10.9 ± 5.9 13.3 ± 7.8 <0.001
Baseline 6-minute walk distance, meters 336 ± 93 322 ± 92 353 ± 91 347 ± 89 <0.001
Drug class, % 0.021
 Endothelin receptor antagonists 71 72 69 67
 Phosphodiesterase 5 inhibitors 12 13 11 13
 Prostacyclin analogs 17 16 20 22
*

Except where indicated otherwise, values are the mean ± SD.

CTD-associated PAH = connective tissue disease–associated pulmonary arterial hypertension; SSc = systemic sclerosis; WHO = World Health Organization.